GOG-0274 RTOG 1174

Closed to Accrual

Return to Protocol Table

A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL

Principal Investigator

Kathleen Moore, MD, MS

Status

Closed to Accrual

Date Opened To Accrual

January 09 2012

Date Closed to Accrual

June 28 2017

Disease Site

Gynecologic [GY]

Cervix

Phase

III

Developmental Therapeutics

Primary Objective

To determine if the addition of adjuvant chemotherapy to standard cisplatin-based chemo-radiation improves overall survival.

Patient Population

Patients with stage IB1 & positive nodes, IB2, II, IIIB or IVA cervical cancer suitable for primary treatment with chemo-radiation with curative intent.

Target Accrual

500

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Study Memos

OUTBACK COVID-19 Deviation Tracking Log and Instructions for Use.pdf

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.